Three industry partnersâAstraZeneca, Eli Lilly andCo., and Pfizerâwill turn over a total of 24 compounds for the pilot phase of a new initiative with the NationalInstitutes of Health's National Centerfor Advancing Translational Sciences called Discovering New Therapeutic Uses for Existing Molecules.
Through grants from NCATS, those compounds will be tested by researchers for efficacy in other diseases and conditions. Each of the compounds has already undergone significant testing, including for safety in humans. The initiative aims to improve on current therapies more quickly.
"Clearly, we need to speed the pace at which we are turning discoveries into better health outcomes," NIH Director Francis Collins,MD, PhD, said in a statement.
In the pilot program, companies will retain the ownership of their compounds. Researchers, meanwhile, own any intellectual property that arises from their work and the right to publish their work.